Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2008 Nov;102(9):1120-7.
doi: 10.1111/j.1464-410X.2008.07939.x. Epub 2008 Oct 6.

Solifenacin in the Treatment of Urgency and Other Symptoms of Overactive Bladder: Results From a Randomized, Double-Blind, Placebo-Controlled, Rising-Dose Trial

Collaborators, Affiliations
Free article
Clinical Trial

Solifenacin in the Treatment of Urgency and Other Symptoms of Overactive Bladder: Results From a Randomized, Double-Blind, Placebo-Controlled, Rising-Dose Trial

Linda Cardozo et al. BJU Int. .
Free article

Abstract

Objectives: To examine the effects of the antimuscarinic agent solifenacin on urinary urgency, using a range of novel and established outcome measures, as urgency is the principal symptom of the overactive bladder syndrome (OAB).

Patients and methods: The study (SUNRISE, solifenacin in the treatment of urgency symptoms of OAB in a rising dose, randomized, placebo-controlled, double-blind, efficacy trial) was a randomized, double-blind, 16-week, placebo-controlled, multicentre study of solifenacin 5/10 mg in 863 patients with symptoms of OAB for > or = 3 months. The primary efficacy variable was the change from baseline to endpoint in the number of episodes of severe urgency with or without urgency incontinence per 24 h, as measured using the Patient Perception of Intensity of Urgency Scale, grade 3 + 4. Secondary efficacy variables included patient-reported outcomes for bladder condition, urgency bother and treatment satisfaction. A 3-day voiding diary was used to record micturition frequency and episodes of urgency and incontinence. A 7-day diary was used to assess speed of onset of effect.

Results: Solifenacin 5/10 mg was significantly more effective than placebo in reducing the mean number of episodes of severe urgency with or without incontinence per 24 h from baseline to endpoint (-2.6 vs -1.8, P < 0.001). There were also statistically significant differences in favour of solifenacin 5/10 mg over placebo for all secondary variables measured at endpoint, including patient-reported outcomes. There was a significant improvement in urgency as early as day 3 of treatment. Treatmente-mergent adverse events with solifenacin 5/10 mg were mainly mild or moderate in severity, and only led to discontinuation in 3.6% of patients.

Conclusion: Solifenacin significantly reduced the number of urgency episodes and the extent of urgency bother, and was well tolerated; it was effective as early as day 3 of treatment.

Comment in

Similar articles

See all similar articles

Cited by 28 articles

See all "Cited by" articles

Publication types

Feedback